[徵paper]兩篇

看板medstudent作者 (喜歡淡綠色)時間11年前 (2012/09/12 10:08), 編輯推噓1(1推 0噓 1→)
留言2則, 2人參與, 最新討論串1/2 (看更多)
Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio Blanco G, Sileri P, Tosetto L, Skoulidis F, Pallone F, Roselli M. Cancer Biomark. 2009;5(4):167-75. Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer. Tsai HL, Chang YT, Chu KS, Chen CF, Yeh YS, Ma CJ, Wu DC, Kuo CH, Chan HM, Sheen MC, Wang JY. Int J Biol Markers. 2008 Oct-Dec;23(4):244-8. 我的信箱是hjj7tony@yahoo.com.tw 感謝您 -- ※ 發信站: 批踢踢實業坊(ptt.cc) ◆ From: 42.76.126.225
推
09/12 10:45, , 1F
sent
09/12 10:45, 1F
→
09/12 16:07, , 2F
謝謝貓大
09/12 16:07, 2F
‣ 更多 Holier 的文章
文章代碼(AID): #1GJ-ww2W (medstudent)
‣ 更多 Holier 的文章
文章代碼(AID): #1GJ-ww2W (medstudent)